In today’s recent session, 52.63 million shares of the Candel Therapeutics Inc (NASDAQ:CADL) have been traded, and its beta is -0.93. Most recently the company’s share price was $10.59, and it changed around $5.98 or 129.72% from the last close, which brings the market valuation of the company to $343.91M. CADL at last check was trading at a discount to its 52-week high of $14.30, offering almost -35.03% off that amount. The share price’s 52-week low was $0.81, which indicates that the recent value has risen by an impressive 92.35% since then. We note from Candel Therapeutics Inc’s average daily trading volume that its 10-day average is 0.64 million shares, with the 3-month average coming to 382.95K.
Candel Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CADL as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Instantly CADL has been showing a green trend so far today with a performance of 129.72% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 14.60 on recent trading dayincreased the stock’s daily price by 27.47%. The company’s shares are currently up 620.41% year-to-date, but still up 139.05% over the last five days. On the other hand, Candel Therapeutics Inc (NASDAQ:CADL) is 127.74% up in the 30-day period. We can see from the shorts that 1.78 million shares have been sold at a short interest cover period of 7.72 day(s).
Candel Therapeutics Inc (CADL) estimates and forecasts
Candel Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 39.71 percent over the past six months and at a -25.95% annual growth rate that is well below the industry average of 17.20%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -46.75%.
CADL Dividends
Candel Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 30.39% of Candel Therapeutics Inc shares, and 22.53% of them are in the hands of institutional investors. The stock currently has a share float of 32.37%. Candel Therapeutics Inc stock is held by 74.0 institutions, with NORTHPOND VENTURES, LLC being the largest institutional investor. By 2024-06-30, it held 6.628% of the shares, which is about 1.94 million shares worth $12.0 million.
BLACKROCK INC., with 2.819% or 0.82 million shares worth $5.1 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
